EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mechanisms of Resistance to Antibody–Drug Conjugates

Rachel Occhiogrosso Abelman iD, Bogang Wu iD, Laura M Spring, Leif W Ellisen iD, Aditya Bardia

Cancers · 17.02.2023 · 15 (4) · 1278

DOI: 10.3390/cancers15041278 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.02.2023. Verfasst von Rachel Occhiogrosso Abelman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Die Arbeit wurde bisher 162-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NRSA T32.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs), with antibodies targeted against specific antigens linked to cytotoxic payloads, offer the opportunity for a more specific delivery of chemotherapy and other bioactive payloads to minimize side effects. First approved in the setting of HER2+ breast cancer, more recent ADCs have been developed for triple-negative breast cancer (TNBC) and, most recently, hormone receptor-positive (HR+) breast cancer. While antibody–drug conjugates have compared favorably against traditional chemotherapy in some settings, patients eventually progress on these therapies and require a change in treatment. Mechanisms to explain the resistance to ADCs are highly sought after, in hopes of developing next-line treatment options and expanding the therapeutic windows of existing therapies. These resistance mechanisms are categorized as follows: change in antigen expression, change in ADC processing and resistance, and efflux of the ADC payload. This paper reviews the recently published literature on these mechanisms as well as potential options to overcome these barriers.

Schlagwörter

Stichwörter der Autor:innen

antibody–drug conjugatesbreast cancertargeted therapies

Autor:innen und Institutionen

  • Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

ORCID-Profile: Rachel Occhiogrosso Abelman, Bogang Wu, Leif W Ellisen

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NRSA T32
  • Terri Brodeur Breast Cancer Foundation
  • NCI R01

Zitieren

APA

Abelman, R. O., Wu, B., Spring, L. M., Ellisen, L. W., & Bardia, A. (2023). Mechanisms of Resistance to Antibody–Drug Conjugates. Cancers, 15(4), 1278. https://doi.org/10.3390/cancers15041278

Vancouver

Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. Mechanisms of Resistance to Antibody–Drug Conjugates. Cancers. 2023;15(4):1278. doi:10.3390/cancers15041278

BibTeX
@article{Abelman2023,
  author = {Abelman, Rachel Occhiogrosso and Wu, Bogang and Spring, Laura M and Ellisen, Leif W and Bardia, Aditya},
  title = {Mechanisms of Resistance to Antibody–Drug Conjugates},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {4},
  pages = {1278},
  doi = {10.3390/cancers15041278}
}
Kostenlos starten →